Abstract
A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a different toxicity profile. In particular, it does not appear to cause bone marrow suppression which is of importance in AIDS patients as many of them are taking concurrent zidovudine.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Commens C. Fixed drug eruption. Australas J Dermatol. 1983 Apr;24(1):1–8. doi: 10.1111/j.1440-0960.1983.tb00240.x. [DOI] [PubMed] [Google Scholar]
- Korkij W., Soltani K. Fixed drug eruption. A brief review. Arch Dermatol. 1984 Apr;120(4):520–524. [PubMed] [Google Scholar]
- Youle M. M., Hawkins D. A., Collins P., Shanson D. C., Evans R., Oliver N., Lawrence A. Acyclovir-resistant herpes in AIDS treated with foscarnet. Lancet. 1988 Aug 6;2(8606):341–342. doi: 10.1016/s0140-6736(88)92402-6. [DOI] [PubMed] [Google Scholar]